The validity of giving adjuvant capecitabine after standard anthracycline and/or taxanes based neo-/adjuvant chemotherapy in early triple-negative breast cancer patients: An Egyptian prospective multicentric phase III trial

Background: Triple-negative breast cancer (TNBC) is considered an aggressive breast cancer subtype despite giving standard therapies, these patients have high metastatic and relapse rates in addition to short survival. Therefore, we conducted this trial to study the validity of giving adjuvant Capec...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Marwa Abdelgawad, loay Gertalla, Alia Attia, Ahmed Hefni, lobna Abdelaziz
Formato:	Artigo
Idioma:	Inglês
Publicado em:	The Egyptian Association for Cancer Research (EACR) 2022-06-01
Colecção:	Egyptian Journal of Cancer and Biomedical Research
Assuntos:	Triple-Negative Breast Cancer Capecitabine Adjuvant Chemotherapy survival safety profile
Acesso em linha:	https://jcbr.journals.ekb.eg/article_253126_e9d04975910274458f197ac6fbcb3f4a.pdf
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!